Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against Commvault Systems, Inc. (NASDAQ: CVLT) related to possible violations of securities laws, focusing on misleading statements and undisclosed information [1] Financial Performance - Commvault reported a 40% growth in SaaS Annual Recurring Revenue (ARR) to $364 million for Q3 2026 [1] - The company noted that 60% of its deals closed in the last few weeks of the quarter, which was perceived negatively by the market [1] Market Reaction - Following the Q3 2026 financial results announcement, Commvault's shares fell approximately 31.1% on the same day, indicating a significant market reaction to the perceived deceleration in business growth [1]

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Great Lakes Dredge & Dock Corporation to Saltchuk Resources, Inc., focusing on whether the offered price of $17.00 per share adequately reflects the company's value and the process leading to this valuation [1]. Group 1: Proposed Sale Details - The proposed transaction involves shareholders of Great Lakes receiving $17.00 in cash for each share they own [1]. - KSF is assessing the adequacy of this consideration and the process that led to the proposed sale [1]. Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can discuss their legal rights with KSF without obligation or cost [1]. - KSF Managing Partner Lewis S. Kahn can be contacted via email or toll-free phone for inquiries related to the investigation [1].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against ICON Public Limited Company due to concerns over accounting practices and internal controls, particularly regarding revenue recognition from fiscal years 2023 to 2025 [1] Group 1: Investigation Details - The investigation is focused on whether ICON and/or its senior management violated federal securities laws or engaged in unlawful business practices [1] - ICON's Audit Committee is currently conducting an investigation into certain accounting practices and internal controls [1] - The company has indicated that it expects to report one or more material weaknesses in internal control over financial reporting [1] Group 2: Financial Impact - Following the announcement of the investigation, ICON's share price fell by $53.06, approximately 40%, from $133.14 on February 11, 2026, to close at $80.08 on the same day [1] - ICON has delayed the release of its fourth quarter and full year 2025 financial results and has withdrawn its previously issued 2025 guidance [1]

Group 1 - The article discusses a class action lawsuit against China Liberal Education Holdings Limited (CLEUF) for securities fraud, with a deadline for filing a lead plaintiff motion set for March 31, 2026 [1] - The lawsuit arises from a significant drop in CLEU's stock price, which fell from $7.75 to $0.148 per share, representing a 98.1% loss, following the disclosure of 240 million previously undisclosed exchanged shares [1] - Allegations in the lawsuit include that the defendants made materially false statements and failed to disclose adverse facts about the company's operations, including involvement in a pump-and-dump scam [1] Group 2 - The article also mentions that CLEU was delisted by NASDAQ in June 2025, further impacting investor confidence [1] - Investors are encouraged to contact Glancy Prongay Wolke & Rotter LLP for more information on participating in the class action lawsuit [1]

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for securities fraud, following significant management departures and issues with financial reporting, leading to a substantial drop in stock price [1]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who acquired Kyndryl securities between August 7, 2024, and February 9, 2026, with a deadline for filing a lead plaintiff motion set for April 13, 2026 [1]. - The lawsuit alleges that Kyndryl made materially false and misleading statements regarding its business operations and financial health during the class period [1]. - Specific allegations include that Kyndryl's financial statements were materially misstated, lacked adequate internal controls, and that the company would be unable to timely file its quarterly report [1]. Group 2: Company Developments - On February 9, 2026, Kyndryl announced the immediate departure of its CFO and General Counsel, which raised concerns about its internal controls and financial reporting practices [1]. - The company indicated it anticipates reporting material weaknesses in its internal control over financial reporting, particularly regarding communication and management practices [1]. - Following these announcements, Kyndryl's stock price fell by $12.90, or 54.9%, closing at $10.59 per share on the same day [1].

Group 1 - The article discusses a class action lawsuit against Charming Medical Limited (MCTA) for securities fraud, with a deadline for shareholders to file a lead plaintiff motion by February 17, 2026 [1] - The lawsuit claims that during the class period from October 10, 2025, to November 12, 2025, the company made materially false and misleading statements regarding its business and operations [1] - The SEC halted trading of Charming securities on November 11, 2025, due to potential manipulation through social media recommendations aimed at artificially inflating the stock price [1] Group 2 - Allegations in the lawsuit include that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company failed to disclose material adverse facts [1] - The complaint asserts that the company's public statements omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - Shareholders who acquired Charming securities during the class period are encouraged to participate in the lawsuit to recover losses under federal securities laws [1]

Core Viewpoint - Investors in uniQure N.V. have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934, specifically related to misleading statements about FDA approval and BLA timelines [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is defined as between September 24, 2025, and October 31, 2025, during which investors are encouraged to contact the firm before April 13, 2026 [1] - The lawsuit claims that uniQure made false and misleading statements regarding its ability to secure full FDA approval for its Pivotal Study and misrepresented the likelihood of delaying its BLA timeline [1] Group 2: Investor Impact - Investors who purchased uniQure's securities during the class period reportedly suffered damages when the truth about the company's misleading statements was revealed [1] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, indicating a focus on protecting shareholder rights [1]

Group 1 - Rosen Law Firm has announced a class action lawsuit on behalf of shareholders of BlackRock TCP Capital Corp. (NASDAQ: TCPC) for the period between November 6, 2024, and January 23, 2026 [1] - The lawsuit alleges that BlackRock TCP misled investors regarding its business operations, including failing to disclose that investments were not being timely or appropriately valued [1] - The firm claims that BlackRock TCP's unrealized losses were understated and its net asset value (NAV) was overstated, leading to materially misleading statements about the company's prospects [1] Group 2 - Shareholders wishing to serve as lead plaintiffs must file motions with the court by April 6, 2026, and they do not need to participate in the case to be eligible for recovery [1] - Rosen Law Firm operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [1] - The firm has a history of obtaining over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, with a deadline for investors to seek lead plaintiff status set for April 6, 2026 [1] Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with its Phase III Orbit study [1] - Defendants are accused of making misleading statements about the company's business and prospects, lacking a reasonable basis for their optimism [1] Group 2: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing for lead plaintiff status by the April 6, 2026 deadline [1] - Options for investors include retaining counsel or taking no action, with the ability to remain an absent class member [1] - The lead plaintiff will represent all class members and is typically the investor with the largest financial interest [1]

Core Viewpoint - Paysafe Limited (PSFE) is facing a class action lawsuit due to alleged securities fraud, following a significant drop in its stock price after disappointing financial results were announced [1] Financial Performance - For Q3 2025, Paysafe reported revenue of $433.8 million, missing consensus estimates by $5.8 million - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year - Full year 2025 expected revenue was revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1] Issues Leading to Lawsuit - The lawsuit alleges that Paysafe's ecommerce business had significant exposure to a single high-risk client, leading to understated credit loss reserves and write-offs - The company faced undisclosed issues with higher risk Merchant Category Codes, complicating its banking relationships - These factors were likely to negatively impact revenue growth and overall revenue mix, making it unlikely for Paysafe to meet its previously issued financial guidance for fiscal year 2025 [1] Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025, with unusually high trading volume [1]